Safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of 9MW1911, an anti-ST2 monoclonal antibody: results from a first-in-human phase 1 study
The study demonstrates that 9MW1911 was safe and well-tolerated in healthy participants. As 9MW1911 concentrations increased,the sustained elevation of sST2 in the higher dose levels (100mg-1200 mg) suggested that the target-mediated drug disposition (TMDD) elimination became saturated, leading to the observed linear PK profile. These data support the continued development of 9MW1911 for the therapeutic use in the relevant disease.
Authors
- Yinhan Guo
- Jing Feng (ORCID: https://orcid.org/0000-0003-2850-0990)
- Yilin Wang (ORCID: https://orcid.org/0000-0002-9946-7879)
- Zhitian Hu
- Diyi Fu (ORCID: https://orcid.org/0000-0003-2847-901X)
- Ni Wu (ORCID: https://orcid.org/0000-0003-0751-3047)
- Da Yin (ORCID: https://orcid.org/0000-0002-4636-6732)
- Qian Li (ORCID: https://orcid.org/0000-0002-6817-0896)
- Rui Chen (ORCID: https://orcid.org/0000-0003-3813-3717)
- Li Li (ORCID: https://orcid.org/0000-0003-2064-2177)
- Qian Zhao (ORCID: https://orcid.org/0009-0001-6879-8392)
- Xue Zhao (ORCID: https://orcid.org/0000-0003-1852-8017)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Bioscience Research (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fphar.2025.1647816
- Citations
- 1
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Science and Technology Commission of Shanghai Municipality
- Peking Union Medical College Hospital
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission